trending Market Intelligence /marketintelligence/en/news-insights/trending/pz-z2bf7hx9xpvt2ytlx3g2 content esgSubNav
In This List

DelMar Pharmaceuticals chairman steps down; replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


DelMar Pharmaceuticals chairman steps down; replacement named

DelMar Pharmaceuticals Inc. said Erich Mohr resigned as chairman of the board to pursue other business opportunities.

The Canada-based drug developer appointed Robert Hoffman, a director of the company, as Mohr's replacement.

Hoffman, Heron Therapeutics Inc.'s CFO and senior vice president of finance, joined the DelMar board in April. He has more than 20 years of experience in financial management, according to S&P Capital IQ.

Mohr founded MedGenesis Therapeutix Inc. in 2005 and also serves as its chairman and CEO. He became the independent chairman of DelMar in 2017, having joined the company's board in 2015, according to S&P Capital IQ.